Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer

Journal of Contemporary Brachytherapy

Volumn 6, Issue 3, 2014, Pages 262-270

  Eldredge Hindy, Harriet Belding ^a   Eastwick, Gary ^a   Anne, Pramila Rani ^a   Rosenblum, Norman G ^b   Schilder, Russell J ^a   Chalian, Raffi ^b   Zibelli, Allison M ^a   Kim, Christine H ^b   Den, Robert ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Clear cell carcinoma; Endometrial cancer; High dose rate brachytherapy; High intermediate risk; Papillary serous

Indexed keywords

CARBOPLATIN; DOCETAXEL; IRIDIUM 192; PACLITAXEL;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; ASCITES FLUID CYTOLOGY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CARCINOMATOSIS; CLEAR CELL CARCINOMA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG DOSE REDUCTION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOLOGY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MYALGIA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; POSTMENOPAUSE; PRURITUS; SALPINGOOOPHORECTOMY; TUMOR INVASION; UROGENITAL TRACT DISEASE; VAGINA DISEASE; VAGINAL BRACHYTHERAPY; VAGINAL DILATOR;

EID: 84907682928     PISSN: 1689832X     EISSN: 20812841     Source Type: Journal    
DOI: 10.5114/jcb.2014.45031     Document Type: Article

References (39)

1. Keys HM, Roberts JA, Brunetto VL et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 744-751.
2. Creutzberg CL, Nout RA, Lybeert ML et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial cancer. Int J Radiat Oncol Biol Phys 2011; 81: E631-e638.
3. ASTEC/EN.5 Study Group, Blake P, Swart AM, Orton J et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomized trials): Pooled trial results, systematic review, and meta-analysis. Lancet 2009; 373: 137-146.
4. Aalders J, Abeler V, Kolstad P et al. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: Clinical and histopathologic study of 540 patients. Obstet Gynecol 1980; 56: 419-427.
5. Nout RA, van de Poll-Franse LV, Lybeert ML et al. Longterm outcome and quality of life in patients with endometrial carcinoma treated with our without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol 2011; 29: 1692-1700.
6. Creutzberg CL, van Putten WL, Koper PC et al. The morbidity of treatment for patients with stage I endometrial cancer: Results from a randomized trial. Int J Radiat Oncol Biol Phys 2001; 51: 1246-1255.
7. Kellas-Sleczka S, Wojcieszek P, Bialas B. Adjuvant vaginal brachytherapy as part of a management in early endometrial cancer. J Contemp Brachyther 2012; 4: 247-252.
8. Creutzberg CL, van Putten WL, Koper PC et al. Survival after relapse in patients with endometrial cancer: Results from a randomized trial. Gynecol Oncol 2003; 89: 201-209.
9. Nout RA, Smit VT, Putter H et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): An open-label, non-inferiority, randomized trial. Lancet 2010; 375: 816-823.
10. Susumu N, Sagae S, Udagawa Y et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate-and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008; 108: 226-233.
11. Greven K, Winter K, Underhill K et al. Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 2006; 103: 155-159.
12. Jutzi L, Hoskins P, Lim P et al. The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma. Gynecol Oncol 2013; 131: 581-585.
13. Ayeni TA, Bakkum-Gamez JN, Mariani A et al. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecol Oncol 2013; 129: 478-485.
14. Gynecologic Oncology Group (GOG). Pelvic radiation therapy or vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with high-risk stage I or II endometrial cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2013 Nov 8]. Available from: Http://clinicaltrials.gov/show/NCT00807768. NLM Identifier: NCT00807768.
15. Alektiar KM, Makker V, Abu-Rustum NR et al. Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer. Gynecol Oncol 2009; 112: 142-145.
16. Tchabo NE, McCloskey S, Mashtare TL et al. Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006. Gynecol Oncol 2009; 155: 249-256.
17. Viswanathan AN, Macklin EA, Berkowitz R et al. The importance of chemotherapy and radiation in uterine papillary serous carcinoma. Gynecol Oncol 2011; 112: 542-547.
18. Growdon WB, Rauh-Hain JJ, Cordon A et al. Prognostic determinants in patients with stage I uterine papillary serous carcinoma: A 15-year multi-institutional review. Int J Gynecol Cancer 2012; 22: 417-424.
19. Kim A, Schreiber D, Rineer J et al. Impact of adjuvant external-beam radiation therapy in early-stage uterine papillary serous and clear cell carcinoma. Int J Radiat Oncol Biol Phys 2011; 81: E639-e644.
20. Barney BB, Petersen IA, Mariani A et al. The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer. Int J Radiat Oncol Biol Phys 2013; 85: 109-115.
21. Yechieli R, Rasool N, Robbins JR et al. Adjuvant radiation therapy for patients with type II endometrial carcinoma: Impact on tumor recurrence and survival. Int J Gynecol Cancer 2013; 23: 763-768.
22. Huh WK, Powell M, Leath CA et al. Uterine papillary serous carcinoma: Comparisons of outcomes in surgical stage I patients with and without adjuvant therapy. Gynecol Oncol 2003; 91: 470-475.
23. Sutton G, Axelrod JH, Bundy BN et al. Adjuvant whole abdominal irradiation in clinical stage I and II papillary serous or clear cell carcinoma of the endometrium: A phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006; 100: 349-354.
24. Kiess AP, Damast S, Makker V et al. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer. Gynecol Oncol 2012; 127: 321-325.
25. Townamchai K, Berkowitz R, Bhagwat M et al. Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer. Gynecol Oncol 2013; 129: 18-21.
26. Creasman WT, Kohler MF, Odicino F et al. Prognosis of papillary serous, clear cell, and grade3 stage I carcinoma of the endometrium. Gynecol Oncol 2004; 95: 593-596.
27. Crisano FD, Robboy SJ, Dodge RK et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 2000; 77: 55-65.
28. Leiden University Medical Center. Randomized trial of radiation therapy with or without chemotherapy for endometrial cancer (PORTEC-3). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2013 Nov 8]. Available from: Http://clinicaltrials.gov/show/NCT00411138. NLM Identifier: NCT00411138.
29. Van der Steen-Banasik E. Primary brachytherapy as a radical treatment for endometrial carcinoma. J Contemp Brachytherapy 2014; 6: 106-112.
30. McMeekin DS, Filiaci VL, Aghajanian C et al. A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): A Gynecologic Oncology Group trial. Proceedings of the 45th Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, Tampa, FL (2014, March 22).
31. Ko EM, Funk MJ, Clark LH et al. Did GOG99 and PORTEC1 change clinical practice in the United States? Gynecol Oncol 2013; 129: 12-17.
32. Albuquerque K, Shah K, Potkul R. Vaginal dehiscence after intracavitary brachytherapy for endometrial cancer. J Contemp Brachytherapy 2012; 4: 111-112.
33. Donnelly ED, Rakhra S, Helenowski I et al. Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial cancer. J Contemp Brachytherapy 2012; 4: 135-140.
34. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Uterine neoplasms, version 3.2012. National Comprehensive Cancer Network; 2012.
35. Atahan IL, Ozyar E, Yildiz F et al. Vaginal high dose rate brachytherapy alone in patients with intermediate-to highrisk stage I endometrial carcinoma after radical surgery. Int J Gynecol Cancer 2008; 18: 1294-1299.
36. McCloskey SA, Tchabo NE, Malhotra et al. Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation. Gynecol Oncol 2010; 116: 404-407.
37. Desai NB, Kiess AP, Kollmeier MA et al. Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation with or without chemotherapy. Gynecol Oncol 2013 (In Press). http://dx.doi.org/10.1016/j. ygyno.2013.09.019.
38. Klopp A, Smith BD, Alektiar K et al. The role of postoperative radiation therapy for endometrial cancer: Executive Summary of the American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2014; 4: 137-144.
39. Randall M, Filiaci V, Muss H et al. Randomized phase III trial of WART versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A GOG study. J Clin Oncol 2006; 24: 36-44.